BEL536

About Belenos Biosciences

Belenos Biosciences is a private, pre-revenue biotech advancing a pipeline of bispecific antibodies targeting key inflammatory pathways. Led by a veteran team with deep experience in drug development and corporate strategy from companies like Biohaven, Pfizer, and Bristol-Myers Squibb, the company is progressing two lead candidates, BEL512 and BEL536, toward Phase 3 trials starting in 2027. The company's strategy focuses on speed and innovation to deliver next-generation therapies for large, underserved chronic inflammatory disease markets.

Therapeutic Areas